Emerald Health chosen as Top 50 TSX Venture winner for 2017

Emerald Health Therapeutics Inc. has been notified by the TSX Venture Exchange that it came in thrid place in the Clean Technology & Life Science sector of the 2017 TSX Venture 50.

“Emerald is thrilled to be part of such an accomplished group of companies, and recognized for its achievements in 2016. While last year was one of transformation for the whole industry, we expect 2017 to be a year of considerable progress for Emerald as we embark on a series of aggressive growth initiatives. We would like to thank our staff and shareholders for continued support and belief in the future of Emerald,” stated Avtar Dhillon, MD, Executive Chairman.

The 2017 TSX Venture 50 is a ranking of the top performers listed on the TSXV, divided into five industry sectors. The companies are selected based on three equally weighted criteria: market capitalization growth, share price appreciation and trading volume. The TSXV has created a video profile on Emerald, which will be distributed on February 23, 2017, along with the official announcement of the winners.

Footnote(s)